Advancements in Bladder Cancer Therapies and Biomarkers

This chapter explores cutting-edge advancements in bladder cancer therapies, including antibody-drug conjugates and HER2-targeted treatments. It also examines the role of circulating tumor DNA in improving clinical decision-making and discusses key studies like the RETAIN-2 trial focused on patient selection for bladder preservation.